Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.7 USD | -0.21% | +3.30% | +68.46% |
May. 01 | Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 | CI |
Apr. 12 | Lipocine Says LPCN 2401 Shows Improved Body Composition in Mid-Stage Trial | MT |
Business Summary
Number of employees: 17
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Oral Delivery Solutions
100.0
%
| 1 | 100.0 % | -3 | 100.0 % | -670.16% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | -3 | 100.0 % | -670.16% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
Anthony DelConte
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Krista Fogarty
AUD | Comptroller/Controller/Auditor | 56 | 18-09-30 |
Corporate Officer/Principal | 55 | 14-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Dana Ono
BRD | Director/Board Member | 71 | 14-01-05 |
Mahesh Patel
CEO | Chief Executive Officer | 67 | 96-12-31 |
John W. Higuchi
BRD | Director/Board Member | 56 | 12-12-31 |
Director/Board Member | 66 | 14-01-05 | |
Jill M. Jene
BRD | Director/Board Member | 51 | 22-04-10 |
Chairman | 52 | 22-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,348,276 | 5,192,543 ( 97.09 %) | 336 ( 0.006282 %) | 97.09 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.46% | 25.14M | |
-1.65% | 103B | |
+6.75% | 101B | |
+6.49% | 23.07B | |
-12.60% | 22.23B | |
-5.38% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- LPCN Stock
- Company Lipocine Inc.